Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases

Cutuli, B.; Lenir, C; Serin, D.; Kirova, Youlia; Gaci, Z; Lemanski, C.; Lafontan, B. De; Zoubir, M.; Maingon, P.; Mignotte, H.; Lara, C. Tunon de; Edeline, Julien; Penault‐Llorca, Frédérique; Romestaing, P.; Delva, Catherine; Comet, B.; Belkacémi, Yazid

doi:10.1016/j.critrevonc.2009.04.002

Cited by 154 publications

(150 citation statements)

References 60 publications

Supporting

Mentioning

113

Contrasting

Unclassified

Order By: Relevance

“…we could not define any occupational specify in this study unless the history of breast cancer in 4 patients family history (Cutuli et al, 2010;Bourthafour and Belbarake, 2011).…”

Section: Discussionmentioning

confidence: 99%

“…Despite a significant raise in the last 25 years , among male patients, it still remains a rare disease (Cutuli et al, 2010). Given its low incidence, few studies have assessed risk and prognosis The literature about male breast cancer consists of retrospective studies and there are no randomized prospective data so the therapy is based on standards admitted from female breast cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinicopathologic Characteristics of Male Breast Cancer: A Report of 21 Cases in Radiotherapy Center of Hamedan, Iran

Sedighi¹,

Hamed²,

Mohammadian³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…we could not define any occupational specify in this study unless the history of breast cancer in 4 patients family history (Cutuli et al, 2010;Bourthafour and Belbarake, 2011).…”

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Clinicopathologic Characteristics of Male Breast Cancer: A Report of 21 Cases in Radiotherapy Center of Hamedan, Iran

Sedighi¹,

Hamed²,

Mohammadian³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…The OS for MBC patients has ranged between 49 and 87% at 5 years (14,25). A more advanced stage and a higher incidence of lymph node metastases have been linked to a poorer prognosis (26). The role of AR as a prognostic factor is controversial.…”

Section: Discussionmentioning

confidence: 99%

Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment

Zhao

Tang

et al. 2014

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Androgen receptor (AR) plays an important role in male breast cancer (MBC). Additionally, endocrine therapy is the most important treatment in oestrogen receptor (ER)-positive advanced breast cancer. This study was aimed to investigate the role of AR in MBC treatment and prognosis and to analyse the relationship between AR and the effect of tamoxifen treatment in MBC patients. Methods: AR protein levels and other tumour characteristics (e.g. expression of ER (ESR1), PR (PGR), AR, HER2 (ERBB2) and Ki-67 (MKI67)) in breast cancer tissue from 102 MBC patients were determined using immunohistochemical analysis. Additionally, the relationship between AR status and clinicopathological features was analysed using the c 2 -test. Association with survival was initially analysed using the Kaplan-Meier method and the log-rank test, and Cox regression analysis was used to adjust for other prognostic indicators.Results: High expression of AR was not correlated with T-stage, histological grade, HER2 status and the status of other sex hormone receptors, but was associated with lymph node metastases (PZ0.032). AR-positive patients showed significantly shorter 5-year overall survival (OS) rates (PZ0.045) and 5-year disease-free survival (DFS) rates (PZ0.026) than AR-negative patients. By contrast, for patients who received tamoxifen therapy, AR-negative patients showed a higher clinical benefit rate than AR-positive patients (PZ0.025). Additionally, the median TTP and OS were significantly different (PZ0.02 for TTP; PZ0.029 for OS). Conclusions: AR expression correlates strongly with both OS and DFS in patients with MBC. AR-positive patients can predict a poorer clinical outcome than AR-negative patients after adjuvant tamoxifen therapy.

show abstract

“…[2][3][4][5][6] Initially, prognosis in men was claimed to be poor with higher incidence of lymph node metastases at the time of discovery, but more recent studies showed that prognosis of male and female breast cancers corrected for stage and age is similar. [7][8][9] Although tumor size and lymph node status are independent prognosticators in male breast cancer, 9,10 there still is a need for more accurate outcome predictors of male breast cancer.…”

mentioning

confidence: 99%

Fibrotic focus and hypoxia in male breast cancer

et al. 2012

View full text Add to dashboard Cite

Fibrotic focus is a scar-like lesion near the center of a carcinoma and has been associated with high-grade, lymph node metastases and poor survival in female breast cancers. Hypoxia is suggested to be the crucial link between fibrotic focus and aggressive tumor phenotype and is also itself a poor prognostic marker. We here set out to study fibrotic focus and hypoxia in male breast cancer for the first time. In a group of 134 male breast cancer patients, the presence and size of a fibrotic focus and the expression of three hypoxia-related immunohistochemical stainings, hypoxia-inducible factor-1a, carbonic anhydrase IX and Glut-1 were studied in correlation with clinicopathological features and prognosis. Fibrotic focus was seen in 25% of the male breast cancer cases and was correlated with hypoxia-inducible factor-1a overexpression (P ¼ 0.023), high grade (P ¼ 0.005), high mitotic activity (P ¼ 0.005) and lymph node metastases (P ¼ 0.037). Hypoxia-inducible factor-1a-positive tumors were more often high grade (P ¼ 0.003) and HER2 amplified (P ¼ 0.005). Glut-1 expression was also more common in grade 3 tumors (P ¼ 0.038), but no association between carbonic anhydrase IX and any clinicopathological feature was found. Fibrotic focus 48 mm and hypoxia-inducible factor-1a overexpression were correlated with decreased patients' outcome (P ¼ 0.035 and 0.008, respectively). Hypoxia-inducible factor1a overexpression was an independent and the most powerful predictor of survival in multivariate analysis (P ¼ 0.029; hazard ratio 2.5). In conclusion, the presence of a fibrotic focus is associated with hypoxia-inducible factor-1a overexpression, and both are associated with aggressive tumor phenotype and poor survival in male breast cancer. These markers seem to have similar clinical importance as previously reported in female breast cancer. Modern Pathology (2012) 25, 1397-1404; doi:10.1038/modpathol.2012.101; published online 8 June 2012Keywords: fibrotic focus; hypoxia; male breast cancer; prognosis Male breast cancer is uncommon and represents o1% of all breast cancers. 1 Large series in male breast cancer are lacking and much of the knowledge is generalized from breast cancer in female subjects. The limited data published on male breast cancer indicate that there are genetic and phenotypic differences between male and female breast cancer. [2][3][4][5][6] Initially, prognosis in men was claimed to be poor with higher incidence of lymph node metastases at the time of discovery, but more recent studies showed that prognosis of male and female breast cancers corrected for stage and age is similar. [7][8][9] Although tumor size and lymph node status are independent prognosticators in male breast cancer, 9,10 there still is a need for more accurate outcome predictors of male breast cancer.A fibrotic focus is a scar-like lesion consisting of an area of mainly collagen and fibroblasts, often located near the center of a carcinoma. Fibrotic focus is associated with poor survival in female breast cancer and with high grade, hig...

show abstract

Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases

Cited by 154 publications

References 60 publications

Clinicopathologic Characteristics of Male Breast Cancer: A Report of 21 Cases in Radiotherapy Center of Hamedan, Iran

Clinicopathologic Characteristics of Male Breast Cancer: A Report of 21 Cases in Radiotherapy Center of Hamedan, Iran

Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment

Fibrotic focus and hypoxia in male breast cancer

Contact Info

Product

Resources

About